Ethylflualprazolam
Benzodiazepine designer drug
From Wikipedia, the free encyclopedia
Ethylflualprazolam is a benzodiazepine derivative[1] which has been sold as a designer drug. It is structurally similar to flualprazolam, only differing by the addition of an ethyl group instead of a methyl group on the triazole ring. Ethylflualprazolam was first detected in samples tested in Toronto, Canada in December 2025 in expected fentanyl samples.[2] It has since been detected by CanTEST in March 2026 in expected alprazolam 'Xanax' and 'RO39' pills.[3]
| Identifiers | |
|---|---|
| |
| ChemSpider | |
| Chemical and physical data | |
| Formula | C18H14ClFN4 |
| Molar mass | 340.79 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Effects
Ethylflualprazolam is a relatively new research chemical, and very little is known about its pharmacological properties.